Finance

Beta
Lists
ARQT:NASDAQ
Arcutis Biotherapeutics Inc
$25.81
-0.12%
(-0.030) 1D
$25.81
0.00% (0.00)
After hours
Closed: Jul 2, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ARQT...
Open
$25.86
High
$26.11
Low
$25.53
Mkt. cap
3.23B
Avg. vol.
1.90M
Volume
1.20M
52-wk high
$31.77
52-wk low
$13.06
EPS
-$0.02
Beta
1.48
Shares outstanding
125.08M
No. of employees
354
Open
$25.86
High
$26.11
Low
$25.53
Mkt. cap
3.23B
Avg. vol.
1.90M
Volume
1.20M
52-wk high
$31.77
52-wk low
$13.06
EPS
-$0.02
Beta
1.48
Shares outstanding
125.08M
No. of employees
354
News stories
From sources across the web
About Arcutis Biotherapeutics Inc
CEOFrank Watanabe
Employees354
Founded2016
HeadquartersWestlake Village, California, United States
SectorBiotechnology
Websitearcutis.com
Analyst ratings
Based on 6 analysts giving stock ratings to ARQT in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ARQT in the last 3 months.
Highest
Current $25.81
$36.00 (+39.48%)
Average
$34.83 (+34.95%)
Lowest
$34.00 (+31.73%)
Analyst
Recommendation
Action
Price target
Projected
Date
Serge Belanger
Needham
Buy
Maintained
$36.00
+39.5%
06/30/2026
Uy Ear
Mizuho Securities
Buy
Reiterated
$35.00
+35.6%
06/03/2026
Seamus Fernandez
Guggenheim
Buy
Maintained
$35.00
+35.6%
05/26/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$34.00
+31.7%
05/11/2026
Judah Frommer
Morgan Stanley
Buy
Maintained
$34.00
+31.7%
05/07/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
$35.00
+35.6%
05/07/2026
Unknown Analyst
Jefferies
Buy
Reiterated
$35.00
+35.6%
03/09/2026
Richard Law CFA
Goldman Sachs
Hold
Maintained
$33.00
+27.9%
02/27/2026
Last report
May 6, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.09 / -$0.06
-55.17%miss
Revenue / Est. (USD)
105.40M / 103.66M
+1.68%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
81.50M
99.22M
129.50M
105.40M
Cost of goods sold
7.49M
8.68M
11.69M
9.78M
Cost of revenue
7.49M
8.68M
11.69M
9.78M
Research and development expenses
19.45M
19.60M
20.45M
30.63M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
69.17M
62.40M
78.98M
74.08M
Operating expense
88.62M
82.01M
99.43M
104.70M
Total operating expenses
96.12M
90.69M
111.12M
114.49M
Operating income
-14.61M
8.53M
18.39M
-9.09M
Other non operating income
-
-
443.00K
-20.00K
EBT including unusual items
-15.54M
7.49M
17.86M
-11.20M
EBT excluding unusual items
-15.54M
7.49M
17.86M
-11.20M
Income tax expense
342.00K
80.00K
470.00K
93.00K
Effective tax rate
-2.20%
1.07%
2.63%
-0.83%
Other operating expenses
-
-
-
-
Net income
-15.89M
7.41M
17.40M
-11.30M
Net profit margin
-19.49%
7.47%
13.43%
-10.72%
Earnings per share
-0.13
0.06
0.13
-0.09
Interest and investment income
2.10M
2.04M
2.04M
2.28M
Interest expense
-3.03M
-3.07M
-3.00M
-4.37M
Net interest expenses
-933.00K
-1.04M
-965.00K
-2.09M
Depreciation and amortization charges
-
-
-
-
EBITDA
-14.20M
9.09M
18.95M
-8.53M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer